L12.3 – Epidermolysis Bullosa Acquisita
L12.3 is the ICD-10 code for Epidermolysis bullosa acquisita, a rare autoimmune skin disease causing blister formation.
Things worth knowing about "L12.3"
L12.3 is the ICD-10 code for Epidermolysis bullosa acquisita, a rare autoimmune skin disease causing blister formation.
What is L12.3? – Epidermolysis Bullosa Acquisita
The ICD-10 code L12.3 refers to Epidermolysis bullosa acquisita (EBA), a rare acquired autoimmune disease affecting the skin and mucous membranes. In this condition, the immune system mistakenly produces antibodies that attack the body's own skin structures, leading to pronounced blister formation that can occur spontaneously or following minimal mechanical trauma.
Causes
The disease is triggered by autoantibodies directed against type VII collagen, a key structural protein that anchors the outer skin layer (epidermis) to the inner layer (dermis). When these anchoring structures are damaged, the skin layers separate and blisters form.
- The exact triggers of the autoimmune response are not fully understood
- A possible genetic predisposition is under investigation
- An association with inflammatory bowel diseases (e.g., Crohn's disease) has been described
Symptoms
The hallmark symptoms of epidermolysis bullosa acquisita include:
- Blister formation on the skin, commonly at pressure points (hands, feet, elbows, knees)
- Wounds and scarring after blisters rupture
- Involvement of mucous membranes (mouth, esophagus, eyes, genitals)
- Itching and burning sensations
- In severe cases: scarring with functional impairment
Diagnosis
Diagnosis requires a combination of clinical examination, laboratory testing, and tissue analysis:
- Skin biopsy with direct immunofluorescence to detect antibody deposits at the dermal-epidermal junction
- Detection of anti-type VII collagen antibodies in the blood (indirect immunofluorescence, ELISA)
- Electron microscopy to precisely localize blister formation
- Exclusion of other blistering conditions (e.g., bullous pemphigoid, pemphigus vulgaris)
Treatment
Treatment of epidermolysis bullosa acquisita is complex and depends on disease severity. Since it is an autoimmune disease, immunosuppressive strategies are central:
- Corticosteroids (e.g., prednisolone) to suppress the immune response
- Dapsone – an antibiotic with anti-inflammatory properties
- Colchicine to modulate the inflammatory response
- Immunosuppressants such as azathioprine, cyclosporine A, or mycophenolate mofetil
- Intravenous immunoglobulins (IVIG) for severe or treatment-resistant cases
- Rituximab (anti-CD20 antibody) as a more recent therapeutic option
- Wound care and skin management to prevent infections
Prognosis
The condition often follows a chronic course with alternating periods of flares and remission. Complete remission is uncommon. The goals of therapy are to reduce blister formation, minimize scarring, and maintain quality of life. Regular dermatological follow-up is essential.
References
- German Institute of Medical Documentation and Information (DIMDI): ICD-10-GM Version 2024, Chapter XII – Diseases of the Skin and Subcutaneous Tissue, L12.3.
- Ujiie H et al.: Epidermolysis bullosa acquisita. In: Journal of Dermatology, 2021; 48(8):1128–1138. PubMed PMID: 34028854.
- Koga H, Recke A, Izumi K et al.: Autoimmune bullous diseases – clinical features, diagnostic workup and therapy. In: JDDG: Journal of the German Society of Dermatology, 2019.
Most purchased products
For your iron balance
Specially formulated for your iron balance with plant-based curry leaf iron, Lactoferrin CLN®, and natural Vitamin C from rose hips.
For your universal protection
As one of the most valuable proteins in the body, lactoferrin is a natural component of the immune system.
For Healthy Oral Flora & Dental Care
Formulated lozenges with Dentalac®, lactic acid bacteria, and Lactoferrin CLN®The latest entries
3 Posts in this encyclopedia categoryMost read entries
3 Posts in this encyclopedia categoryMagnesiumcarbonat
Calorie content
Cologne list
Related search terms: L12.3